Tetraphase Pharmaceuticals Inc (TTPH) is Downgraded by Gabelli & Co to Hold, Price Target at $7

Tetraphase Pharmaceuticals Inc (TTPH) was Downgraded by Gabelli & Co to ” Hold” and the brokerage firm has set the Price Target at $7. Earlier the firm had a rating of “Buy ” on the company shares. Gabelli & Co advised their investors in a research report released on May 13, 2016.

Many Wall Street Analysts have commented on Tetraphase Pharmaceuticals Inc. Shares were Reiterated by Wedbush on May 13, 2016 to “Outperform” and Lowered the Price Target to $ 4 from a previous price target of $8 .

On the company’s financial health, Tetraphase Pharmaceuticals Inc reported $-0.50 EPS for the quarter, missing the analyst consensus estimate by $ -0.08 based on the information available during the earnings call on Feb 23, 2016. Analyst had a consensus of $-0.42. The company had revenue of $2.50 million for the quarter, compared to analysts expectations of $3.34 million. The company’s revenue was down -19.4 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.69 EPS.

Tetraphase Pharmaceuticals Inc opened for trading at $4.54 and hit $4.73 on the upside on Tuesday, eventually ending the session at $4.63, with a gain of 1.98% or 0.09 points. The heightened volatility saw the trading volume jump to 5,30,778 shares. Company has a market cap of $169 M.

In a different news, on Sep 10, 2015, John Craig Thompson (Chief Operating Officer) sold 10,000 shares at $44.08 per share price. According to the SEC, on Sep 3, 2015, Guy Macdonald (President and Chief Executive) sold 10,000 shares at $41.57 per share price. On Aug 17, 2015, David Charles Lubner (SVP and CFO) sold 9,500 shares at $42.92 per share price, according to the Form-4 filing with the securities and exchange commission.

Tetraphase Pharmaceuticals Inc. (Tetraphase) is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create novel antibiotics for serious and life-threatening multidrug-resistant infections. The Company is engaged in developing its product candidate eravacycline which is a fully synthetic tetracycline derivative as a spectrum intravenous (IV) and an oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections including multidrug-resistant Gram-negative infections. TP-271 is a fully synthetic broad-spectrum preclinical compound that the Company developed for respiratory diseases caused by bacterial biothreat pathogens. The Company created TP-271 using its chemistry technology. In its development program for TP-271 the Company has conducted a number of in vitro toxicology and animal studies to evaluate the efficacy of TP-271 against biothreat pathogens.

Tetraphase Pharmaceuticals Inc

Leave a Reply

Tetraphase Pharmaceuticals Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Tetraphase Pharmaceuticals Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.